View Post

Preliminary Data from Phase 1 Study Evaluating ADXS-NEO Suggest Rapid Immunogenicity and Clinical Activity

In Clinical Trials by Barbara Jacoby

Provider: Business Wire From: apnews.com Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces the presentation of ADXS-NEO data in a poster discussion entitled “ Safety and Immunogenicity of a Personalized Neoantigen-Listeria Vaccine in Cancer Patients” at the American Association for Cancer Research (AACR) Annual Meeting underway in Atlanta. The discussion …

View Post

Findings About Children’s Solid Tumors Are Sparking New Therapies

In Clinical Trials by Barbara Jacoby

By: Beth Fand Incollingo From: curetoday.com Compared with solid tumors in adults — about which scientists are learning more and more — those that occur in children are mysteries. Not only are pediatric tumors rare, but they arise in developing tissues, making them difficult to study and treat. That’s where the Childhood Solid Tumor Network (CSTN), run by St. Jude …

View Post

Yuhan Corp and Sorrento Therapeutics Announce Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001

In Clinical Trials by Barbara Jacoby

Source: Sorrento Therapeutics, Inc. From: apnews.com Yuhan Corporation (000100.KS; Yuhan) and Sorrento Therapeutics, Inc. (Nasdaq: SRNE) announced today that ImmuneOncia, a joint venture formed in September 2016, has completed the Phase 1 study of IMC-001 (also known as STI-3031), a fully human anti-PD-L1 monoclonal antibody (mAb) immune checkpoint inhibitor. This Phase 1 dose-escalation study, approved by the South Korean Ministry …

View Post

NKMax America Announces FDA Approval of IND for Phase 1 Trial of SNK01 in Patients with Refractory Cancer

In Clinical Trials by Barbara Jacoby

Source: NKMax America, Inc. From: prnewswire.com NKMax America, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell therapies, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for SNK01, an autologous NK cell adoptive immunotherapy candidate for the treatment of patients …

View Post

Chimeric Antigen Receptor (CAR) T-Cell Clinical Trial

In Clinical Trials by Barbara Jacoby

From: mesothelioma.net An exciting new immunotherapy treatment is now being tested in a phase I clinical trial that is still recruiting for participants. This provides a unique opportunity for patients who qualify to get access to an innovative medicine with great promise. Known as CAR T-cell therapy, this new treatment uses gene therapy to modify a patient’s immune system cells. …

View Post

Servier, in Collaboration with Allogene Therapeutics, Announces FDA Clearance of the IND for ALLO-501, an anti-CD19 Allogeneic CAR T (AlloCAR T) Therapy

In Clinical Trials by Barbara Jacoby

Source: Allogene Therapeutics Allogene to Initiate the ALPHA Study for ALLO-501 in Relapsed/Refractory Non-Hodgkin Lymphoma ALLO-647, Allogene’s Proprietary anti-CD52 Antibody, Will be Administered as Part of the Lymphodepletion Regimen Paris (France) and South San Francisco, Calif. – January 28, 2019 – Servier, an independent international pharmaceutical company and Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical- stage biotechnology company pioneering the …

View Post

City of Hope opens CAR T trial for HER2 breast cancer patients with brain metastases

In Clinical Trials by Barbara Jacoby

Source: City of Hope From: eurekalert.org City of Hope opens first-of-its-kind CAR T clinical trial for patients with HER2-positive breast cancer that has spread to the brain The immunotherapy trial is the first to deliver CAR T cells directly to the brain of HER2-positive breast cancer patients with brain metastases DUARTE, Calif. — Women with HER2-positive breast cancer that has …

View Post

First-in-Human Trial Launched for Super-Enhancer Inhibitor GZ17-6.02

In Clinical Trials by Barbara Jacoby

SOURCE: Translational Drug Development From: apnews.com Genzada Pharmaceuticals USA Inc., a subsidiary of Ionics Life Sciences Limited (Genzada), announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for a Phase 1 human clinical trial of the company’s flagship molecule GZ17-6.02 (6.02) for patients with advanced solid organ tumors or lymphoma. “We …

View Post

Oncoceutics Completes First-in-Man Study of ONC201

In In The News by Barbara Jacoby

Oncoceutics, Inc. announced that enrollment has been completed in the first-in-man phase I dose escalation study of its lead compound, ONC201. The trial, identified as NCT02250781 on www.clinicaltrials.gov and entitled “Oral ONC201 in Treating Patients with Advanced Solid Tumors,” was carried out at Rutgers Cancer Institute of New Jersey (CINJ) under the leadership of principal investigator Mark Stein, MD. The …

Immunotherapy: The next frontier in cancer treatment?

In In The News by Barbara Jacoby

From MedCity News by Veciana-Suarez, Ana Though radiation sent Coris Shepard to the hospital with a burned esophagus for 21 days, it did little to the tumors in his left lung. The chemotherapy that followed didn’t work either. In fact, the stubborn cancer actually grew in size. At wit’s end and almost out of hope, he agreed to participate in …